Liothyronine Sodium CAS:55-06-1

Triiodothyronine, also known as T3, is a thyroid hormone. It affects almost every physiological process in the body, including growth and development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. This pathway is regulated via a closed-loop feedback process: Elevated concentrations of T3, et T4 in plasmate sanguinis inhibent productionem glandulae pituitae TSH. Ut concentraciones horum hormones decrescentes, glandulam pituitariam auget productionem TSH, et his processibus, a feedback imperium systema constituitur ad moderandum quantum hormones thyroideae, quae sunt in rivo sanguinis.

Ut verum hormone, effecta T3 in fibrarum scopo fere quadruplo potentiora sunt quam illae T4.Of thyroideae hormonum productae., iustus de 20% est T3 *, cum 80% produci ut T4. fere 85% circulationem T3 postea in thyroideae formatur per remotionem atomi iodi a carbonis Atomis numero quinque anuli exterioris T4.. In omni causa, retrahitur plasmatis sanguinis humani T3 circa quadragesimum illud T4 .. Hoc etenim observatur propter brevem dimidiae vitae T3 ., quod est solum 2.5 days.This comparat cum dimidia vita T4, quae est de 6.5 diebus.

Liothyronine est potissima forma thyroideae hormon. Chemically, fere idem est cum triiodothyronine (T3). In quantum huiusmodi, it acts on the body to increase the basal metabolic rate, affect protein synthesis and increase the body’s sensitivity to catecholamines (such as adrenaline) by permissiveness. The thyroid hormones are essential to proper development and differentiation of all cells of the human body. These hormones also regulate protein, fat, and carbohydrate metabolism, affecting how human cells use energetic compounds.

In comparison to levothyroxine (T4), liothyronine has a faster onset of action as well as a shorter biological half-life, which may be due to less plasma protein binding to thyroxine-binding globulin and transthyretin.

Physicians can use this instead of or in addition to levothyroxine (T4) for patients undergoing thyroid withdrawal. When a patient has thyroid cancer or Graves’ disease, ablation therapy with radioactive iodine can be used to remove any trace thyroid tissue. For 131I therapy to be effective, the trace thyroid tissue must be avid to iodine. The best method is to starve the tissue of iodine but this can lead to hypothyroid symptoms for the patient. Withdrawal from levothyroxine can be done but it takes six weeks of withdrawal for the remaining thyroid tissue to be completely starved. Six weeks is needed owing to levothyroxine’s long half life. Six weeks can be inconvenient for the patient and delay treatment. Liothyronine instead can be taken and withdrawn from for two weeks to starve the thyroid tissue. Hoc est multo tutius et commodius quam levothyroxinum.